ERBB2 and neoplasm: Early clinical trials with tanespimycin in combination with the monoclonal HER-2 antibody, traztuzumab, showed modest clinical activity in 5 of 25 traztuzumab refractory patients with HER-2 overexpressing tumours (Modi et al, 2007b).